Answers are grounded in this paper and cite their sources.
Narrative review summarizes systemic therapeutic options for hidradenitis suppurativa, highlighting the expanding role of biologic and targeted immunomodulatory agents.
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels that severely impair the quality of life. Management is multifaceted, with systemic antibiotics like oral tetracyclines and clindamycin-rifampicin commonly used as first-line therapy, although growing concerns regarding relapse and antibiotic resistance persist. Retinoids such as acitretin show benefit in select phenotypes but are limited by side effects. Immunomodulatory biologics have transformed HS treatment; adalimumab remains the most established agent, with improved outcomes when initiated early, used continuously, or combined with surgery or antibiotics. Infliximab provides an effective alternative for severe, refractory cases but is limited by immunogenicity. Interleukin-17 (IL-17) inhibitors, including secukinumab and bimekizumab, offer high response rates and durable results, while newer agents like brodalumab and ixekizumab expand treatment options. IL-1 and Janus kinase inhibitors play a promising investigational role in HS treatment. Early, personalized, and interdisciplinary care is essential for achieving durable disease control.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: